Molecular docking of competitive phosphodiesterase inhibitors

Molecular Pharmacology

Volumn 61, Issue 1, 2002, Pages 20-25

  Dym, Orly ^a   Xenarios, Ioannis ^a   Ke, Hengming ^b   Colicelli, John ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE INHIBITOR; ROLIPRAM;

ARTICLE; BINDING SITE; DRUG PROTEIN BINDING; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; SECOND MESSENGER;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC AMP; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; MUTATION; PHOSPHODIESTERASE INHIBITORS; PROTEIN CONFORMATION; ROLIPRAM;

EID: 0036142527     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.61.1.20     Document Type: Article

References (28)

1. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues
2. Identification of inhibitor specificity determinants in a mammalian phosphodiesterase
3. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease
4. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633
5. Hormonal regulation of cyclic nucleotide phosphodiesterases
6. Cyclic nucleotide phosphodiesterases: Relating structure and function
7. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules
8. Automated docking of flexible ligands: Applications of AutoDock
9. Inhibition of bronchospasm and ozone-induced airway hyperresponsiveness in the guinea-pig by CDP840, a novel phosphodiesterase type 4 inhibitor
10. Tailoring cAMP-signalling responses through isoform multiplicity
11. Role of conserved histidines in catalytic activity and inhibitor binding of human recombinant phosphodiesterase 4A
12. Characterization of the structure of a low Km, rolipram-sensitive cAMP phosphodiesterase. Mapping of the catalytic domain
13. Conformational difference between PDE4 apoenzyme and holoenzyme
14. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function
15. Human phosphodiesterase 4A: Characterization of full-length and truncated enzymes expressed in COS cells
16. Use of a yeast expression system for the isolation and analysis of drug-resistant mutants of a mammalian phosphodiesterase
17. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor
18. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4
19. Stereospecific binding of the antidepressant rolipram to brain protein structures
20. Receptor-based 3DQSAR analysis of estrogen receptor ligands - Merging the accuracy of receptor-based alignments with the computational efficiency of ligand-based methods
21. Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions
22. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: Comparison with rolipram
23. The potential of PDE4 inhibitors in asthma or COPD
24. Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future?
25. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast
26. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram
27. LIGPLOT: A program to generate schematic diagrams of protein-ligand interactions
28. Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity